Pumitamig (BNT327) is a new bispecific antibody showing promise for patients with metastatic triple-negative breast cancer, including those who are PD-L1 negative and previously had limited immunotherapy options. The drug works by targeting two pathways at once: it blocks PD-L1 to unleash T cells against tumors and inhibits VEGF to stop tumor blood vessel growth. […]
Emerging strategies in renal cell carcinoma are focusing on new drugs and personalized approaches to improve patient outcomes. Next-generation kinase inhibitors like Zanzalintinib show promise with high disease control rates in early trials. The Phase 3 STELLAR-304 study is testing it with Nivolumab as frontline therapy for non-clear cell RCC. Hypoxia-inducible factor (HIF)-2α inhibitors are
Next-Generation Drugs and Microbiome Approaches Drive Advances in renal cell carcinoma Read More »
Positive results from the Phase 3 TALAPRO-3 trial show that a new combination therapy can significantly delay disease progression in patients with metastatic castration-sensitive prostate cancer who carry HRR gene mutations. The study evaluated Talazoparib combined with Enzalutamide in patients whose cancer has spread but still responds to hormone therapy. This group represents about 25%
Researchers at University of California San Francisco have developed a new approach that could transform CAR-T cell therapy by turning it into a simple injection instead of a complex lab procedure. Traditional CAR-T therapy requires removing a patient’s immune cells, modifying them in a lab, and reinfusing them weeks later. This process is slow, expensive,
UCSF Breakthrough Turns CAR-T cell therapy Into a One-Step Injection Read More »
Two major phase 3 trials, CLL17 and FLAIR, are reshaping treatment for chronic lymphocytic leukemia by comparing continuous therapy with time-limited, personalized approaches. The CLL17 trial compared three chemotherapy-free options: continuous Ibrutinib, time-limited Venetoclax plus Obinutuzumab, and time-limited Ibrutinib plus Venetoclax. All showed similar effectiveness, with about 95% progression-free survival at three years. However, patients
The combination of enfortumab vedotin and pembrolizumab has reshaped treatment for urothelial cancer, showing strong results across multiple stages of the disease. In metastatic patients, it nearly doubled median overall survival compared to chemotherapy (31.5 vs. 16.1 months). In perioperative settings for cisplatin-ineligible muscle-invasive bladder cancer, it reduced the risk of progression or death by
Long-term results from the COMPASSION-03 trial show that cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, offers lasting survival benefits for patients with recurrent or metastatic cervical cancer who have failed prior chemotherapy. Patients who achieved complete responses had a 100% survival rate at 24 months, while partial responders showed a 63% survival rate, with a median
New results from the ASCO Genitourinary Cancers Symposium highlight advances in renal cell carcinoma (RCC) treatment, focusing on the use of belzutifan. In the adjuvant setting, the LITESPARK-022 trial showed that combining belzutifan with pembrolizumab improved disease-free survival compared with pembrolizumab alone. While high-grade side effects were more frequent, most patients tolerated treatment, suggesting this
Three-year follow-up results from the Phase 3 RATIONALE-309 trial show that adding tislelizumab to chemotherapy significantly improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma. Patients receiving the combination of tislelizumab with chemotherapy lived longer and had better disease control compared to chemotherapy alone. Median progression-free survival was 9.6 months versus 7.4 months, while
Tislelizumab Plus Chemotherapy Improves Long-Term Survival in Nasopharyngeal Cancer Read More »
Extended follow-up from a Phase 2a trial shows that CAN-2409, an experimental “in situ” tumor vaccine, may significantly improve survival in patients with advanced non–small cell lung cancer (NSCLC) who no longer respond to immune checkpoint inhibitors. At 24 months, 50% of patients were still alive, an increase from earlier results. Median overall survival reached
CAN-2409 Tumor Vaccine Shows Promising Survival Gains in Advanced Lung Cancer Read More »